Global Plasma Protease C1-inhibitor Treatment Market, by Drug Type (C1-inhibitors, Kallikrein Inhibitor, and Selective Bradykinin B2 Receptor Antagonist), by Dosage (Lyophilized and Injectable), by Distribution Channel (Hospital Pharmacies, Retail Pharmacies, and Online Pharmacies), and by Region (North America, Latin America, Europe, Asia Pacific, Middle East, and Africa) is estimated to be valued at US$ 3,289.5 million in 2020 and is expected to exhibit a CAGR of 18.2% during the forecast period (2020-2027), as highlighted in a new report published by Coherent Market Insights.
Plasma protease C1-inhibitor treatment market is expected to witness significant growth during forecast period, owing to increasing product approvals. For instance, in June 2017, CSL Behring, a global biopharmaceutical company, received the U.S. Food and Drug Administration for HAEGARDA (C1 Esterase Inhibitor Subcutaneous (Human)), the first and only subcutaneous therapy indicated for routine prophylaxis to prevent hereditary angioedema (HAE) attacks in adolescent and adult patients.
Moreover, increasing focus of the major biopharmaceutical companies on development of C1-inhibitor therapies/ drugs is another factor contributing to growth of the Plasma protease C1-inhibitor treatment market. For instance, on October 31, 2019, Ionis Pharmaceuticals, Inc. initiated phase 2 clinical study to evaluate the clinical efficacy, safety, and tolerability of IONIS-PKK-LRx in participants with hereditary angioedema (HAE) type 1 (HAE-1), HAE type 2 (HAE-2), or HAE with normal C1-inhibitor (C1-INH) and to evaluate the effect of IONIS-PKK-LRx on plasma prekallikrein (PKK) and other relevant biomarkers.
Global Plasma Protease C1-inhibitor Treatment Market – Impact of Coronavirus (COVID-19) Pandemic
- The spread of the novel coronavirus has hampered growth of the healthcare industry and the virus has spread rapidly across the globe causing a concerning number of fatalities. In March 2020, the World Health Organization (WHO) declared COVID-19 as a global pandemic and suggested implementation of strict measures to minimize the spread of this disease. The outbreak of COVID-19 has created challenges for several industries and markets worldwide.
- According the World Health Organization, from December 2019, the manifestation of coronavirus disease (COVID-19) resulted in over 36.6 million infected individuals worldwide as of October 2020.
- Various research institutes and biopharmaceutical companies are engaged in study the effects of plasma protease C1-inhibitors in treating significant systemic abnormalities in patients with COVID‐19. In April 2020, Pharming Group N.V. announced the encouraging results from five patients with confirmed COVID-19 (SARS-CoV-2) infections hospitalized with related severe pneumonia that were treated with RUCONEST (recombinant human C1 inhibitor) under a compassionate use program at the University Hospital Basel, Switzerland.
- Thus, such positive results of the plasma protease C1-inhibitors in treating COVID-19 patients is anticipated to provide a significant growth opportunity for Plasma Protease C1-inhibitor Treatment Market.
Browse 32 Market Data Tables and 30 Figures spread through 186 Pages and in-depth TOC on “Million by 2027– Impact of Coronavirus (COVID-19) Pandemic
Global Plasma Protease C1-inhibitor Treatment Market, by Drug Type (C1-inhibitors, Kallikrein Inhibitor, and Selective Bradykinin B2 Receptor Antagonist), by Dosage (Lyophilized and Injectable), by Distribution Channel (Hospital Pharmacies, Retail Pharmacies, and Online Pharmacies), and by Region (North America, Latin America, Europe, Asia Pacific, Middle East, and Africa).
To know the latest trends and insights prevalent in the Global Plasma Protease C1-inhibitor Treatment Market, click the link below:
There are several U.S. FDA approved plasma protease C1-inhibitors for the treatment of HAE-C1-INH (Hereditary angioedema C1 esterase inhibitor (C1-INH)). These products include two human pdC1-INH concentrates – pasteurized, nanofiltered C1-INH (pnfC1-INH) concentrate (Berinert, CSL Behring GmBH, Marburg, Germany) and nanofiltered C1-INH (nfC1-INH) concentrate (Cinryze, ViroPharma Inc., PA, USA/Cetor, Sanquin Blood Supply, Amsterdam, The Netherlands), and recombinant C1-INH produced from transgenic rabbits (rhC1-INH), conestat alfa (Rhucin, Santarus Inc., CA, USA), Ruconest, (Pharming NV, Leiden, The Netherlands). Thus availability of such products in the market is contributing growth of the global plasma protease C1-inhibitor treatment market.
Key Takeaways of the Global Plasma Protease C1-inhibitor Treatment Market:
- The global plasma protease C1-inhibitor treatment market is expected to exhibit a CAGR of 18.2% during the forecast period due to increasing number of clinical trial projects to evaluate the efficiency of the C1-inhibitors in various underlying diseases such as hereditary angioedema type I and II, C1 esterase inhibitor deficiency, and others.
- Among dosage form segment, lyophilized segment is expected to hold significant market share over the forecast period, owing to increasing practice of intravenous administration of drugs for the treatment of HAE and rising demand for intravenous/ lyophilized C1 esterase inhibitor drugs.
- Key players operating in the global plasma protease C1-inhibitor treatment market include CSL Behring LLC, Takeda Pharmaceutical Company Limited, Ionis Pharmaceuticals, Inc., Pharming Technologies B.V., Centogene AG, BioCryst Pharmaceuticals, and KalVista Pharmaceuticals, Inc.
